The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Canaccord Genuity hires Harrison Wehner as Managing Director; Continues building global Life Sciences practice

Thursday, November 08, 2012

Canaccord Genuity hires Harrison Wehner as Managing Director; Continues building global Life Sciences practice11:58 EST Thursday, November 08, 2012 NEW YORK, Nov. 8, 2012 /PRNewswire/ - Canaccord Genuity is pleased to announce the continued expansion of its Life Sciences practice, adding senior investment banker, Harrison Wehner to its global team. Harrison joins Canaccord Genuity as a Managing Director focused on biotechnology and specialty pharmaceuticals and will be based at the firm's Boston office. Over the past several months, Canaccord Genuity has significantly expanded its global Life Sciences practice with additions in the UK, Australia and the US. "We are very pleased to add Harrison's talent and experience to our growing Life Sciences practice," said Jeff Barlow, Managing Director and Head of US Investment Banking. "This is clearly a very interesting time in emerging therapeutics. We believe we have the team in place and expertise to play an increasingly active role in assisting companies in this sector with their financing and financial advisory needs." Harrison Wehner joins Canaccord Genuity from Citigroup where he served as a Managing Director in the Global Healthcare Group in New York and London. Prior to Citigroup, Mr. Wehner held positions at UBS Investment Bank in London and UBS Warburg and PaineWebber in New York. Harrison has 17 years of experience in initiating and executing mergers, acquisitions and securities offerings for biotechnology and technology companies. Harrison received an MBA from the Ross School of Business at the University of Michigan and a BA from the College of William and Mary. With the addition of Harrison, Canaccord Genuity's global Life Sciences team consists of fifteen senior investment bankers located in five geographies: the US, Canada, UK, Australia and Asia. This banking team, combined with eight senior analysts and a specialized sales force in the sector, make Canaccord Genuity one of the leading investment banks focused on Life Science growth companies. ABOUT CANACCORD GENUITY: Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (TSX: CF, LSE: CF.), offering institutional and corporate clients idea-driven investment banking, merger and acquisition, research, sales and trading services from offices in 11 countries worldwide.  Our team of nearly 1,000 capital markets and advisory professionals has industry and transactional expertise in 18 key sectors of the global economy.  We are committed to providing valued services to our clients throughout the entire lifecycle of their business and operating as a gold standard independent investment bank - expansive in resources and reach, but targeted in industry expertise, market focus and individual client attention. More information is available at: www.canaccordgenuity.com ABOUT CANACCORD FINANCIAL INC.: Through its principal subsidiaries, Canaccord Financial Inc. is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and global capital markets.  Since its establishment in 1950, Canaccord has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional and corporate clients through comprehensive investment solutions, brokerage services and investment banking services.  Canaccord has offices in 12 countries worldwide, including Wealth Management offices located in Canada, Australia, the UK and Europe.  Canaccord Genuity, the international capital markets division, operates in Canada, the US, the UK, France, Germany, Ireland, Italy, Hong Kong, mainland China, Singapore, Australia and Barbados. Canaccord Financial Inc. is publicly traded under the symbol CF on the TSX and the symbol CF. on the London Stock Exchange. SOURCE Canaccord Genuity Inc.For further information: <p> Nadine Miller<br/> Canaccord Genuity<br/> 617.371.3842<br/> <a href="mailto:nmiller@canaccordgenuity.com">nmiller@canaccordgenuity.com</a> </p>